GSK wins US approval for ROS1 lung cancer therapy
RegulatoryapprovedJideytroPositive
AI Analysis
Summary
GlaxoSmithKline received US FDA approval for Jideytro, a ROS1-positive lung cancer therapy indicated for previously treated patients. This regulatory approval represents a significant milestone for GSK's oncology portfolio.
Outcome Details
US FDA approval for ROS1 lung cancer therapy for previously treated patients
Importance:8/10
Sentiment:
0.85
FDA approvaloncologylung cancerROS1GSK
Related Companies
Read the original article
Published by PharmaTimes on July 23, 2026 7:49 AM